Excellent prognosis of patients with intermediate-risk neuroblastoma and residual tumor postchemotherapy
jpedsurg.org shows its articles on its own site.
Read the article on jpedsurg.org ↗Article · Nov 2017 · 1 min read
In brief
In brief
Retrospective study of 25 intermediate-risk neuroblastoma patients demonstrates excellent long-term survival regardless of residual tumor resection after chemotherapy. Pathologic analysis showed chemotherapy induced tumor regression or maturation in most cases, suggesting residual tumor resection may be unnecessary in this patient population.
Written by the GCMD Library team from the article.
Background/purpose
The prognosis of patients with intermediate-risk neuroblastoma is favorable; therefore, a reduction therapy is desired. However, the long-term prognosis of those with residual tumor is unclear. The aim of this study was to clarify the necessity of residual tumor resection.
Methods
We retrospectively reviewed the records of patients diagnosed with intermediate-risk neuroblastoma who either were treated by chemotherapy only (nonresection group; n=16), or received postchemotherapy tumor resection (resection group; n=9).
Results
In the nonresection group, tumor size decreased in 14 patients; 5 had no detectable local tumor at the end of the follow-up period. Tumor size increased in 2 patients 1.5–2.5years postchemotherapy. Both patients received additional treatment and survived. All patients survived during the median follow-up time of 127months. In the resection group, 5 patients received complete resections and 4 patients received nearly complete resections. All patients survived during the median follow-up time of 84months. In 8 out of 9 resected tumors, regression or maturation was pathologically induced by chemotherapy-only treatment.
Conclusion
Patients with intermediate-risk neuroblastoma with or without postchemotherapy residual tumor resection had an excellent long-term outcome. The tumor pathology with intermediate-risk neuroblastoma might be susceptible to change to regression or maturation by chemotherapy.
Level of evidence
IV